Back to Agenda
SLS21 “Where, What, and How” of Clinical Trial Information Required by Patients: Disclosure of Investigator Site Name and Clinical Trial Results
Session Chair(s)
Miyoko Yamauchi
Head, Human Capital Development Group , CHUGAI PHARMACEUTICAL CO., LTD., Japan
Speaker(s)
Ryuji Hattori, MPHARM
Development Operation, Pfizer Japan Inc., Japan
Kazuyuki Suzuki, MSC
Feasibility Manager,Devlopment SSO protfolio, Novartis Pharma K.K., Japan
Have an account?